Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
about
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandardSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationVascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerItraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancerThe fate of chemoresistance in triple negative breast cancer (TNBC)Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsRisk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-AnalysisAddition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroupsCorneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewHealth economic aspects of breast cancer treatment: the compulsory health insurances' viewThe microenvironment in breast cancer progression: biology and implications for treatmentLessons learned from the bevacizumab experienceReview of systemic therapies for locally advanced and metastatic rectal cancerContemporary use of bevacizumab in ovarian cancerBevacizumab treatment for advanced breast cancerBevacizumab in ovarian cancer: A critical review of phase III studiesPharmacotherapy for recurrent ovarian cancer: current status and future perspectivesProteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclearSwitching off malignant mesothelioma: exploiting the hypoxic microenvironmentA synthesis of clinical recommendations and primary research for survivors of prostate or breast cancer.Oncologic Angiogenesis Imaging in the clinic---how and why.First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.Treatment-related mortality with everolimus in cancer patients.Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis.Risks and benefits with bevacizumab: evidence and clinical implications.Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.[Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis].
P2860
Q21090878-BB4FB316-0A18-4F84-8E9B-03FEE7AFC57FQ24193614-2FFBF9A7-4AA4-4007-B724-7842E1DCC3ADQ24195003-68C8805F-295D-4DC1-9F1D-E268ECCA7D28Q24202199-1E6F870F-DD86-4FDE-B463-1498105916ADQ24632703-9C3DBE8C-5AA0-4C27-8600-1D83E790E411Q26775232-37E96771-F82B-415D-AB1C-4BB38BC76B24Q26779221-A32120A9-4AB0-401C-A92B-F31539F1EAB8Q26783779-9BA5F076-8ADB-4B3E-9E4F-C6653545F516Q26822395-488D7DDB-2B06-4084-B3B9-9F836B909174Q26823757-3CB214A2-8724-4852-A815-5EE104F907AEQ26824086-8DFBFFFD-6AD0-4282-9212-FE7934283F89Q26826505-5607A15D-75D6-4164-AF03-A5AB97693BE3Q26851314-9C07DF63-9AE5-4D9C-9778-D13565CB5489Q26852509-A522C93C-6B71-4705-A87B-D914F77B7449Q27021105-988D5106-27CA-4E67-B6C1-197511BDDFB9Q27023510-EA9D0E7C-B5C6-404F-87DD-A32CECDE69FAQ27027498-08A496EF-8CA3-4D31-8C86-48CCD75D5FBBQ28076188-5ACF2F54-598C-4B9F-ABE1-AAF648F5D5E6Q28083801-97552E41-4880-49BB-88FA-3297D46383BCQ28482364-8B076011-95B1-4342-A7D7-9246B84BFA02Q29248727-2349D3C5-4B3A-4DF6-9AA4-93B1060DD31DQ30301267-06F9B0CF-0576-4647-9F16-C705EDFE6555Q30472751-ADDBC713-50F8-4ACA-AD89-9A96348AF343Q30657829-B75552CE-6317-4975-B078-0A6A3129D2DDQ31060162-B5F1E6CB-2689-49AA-9A0E-90130ABE39E9Q31152878-51668F93-B925-4EDE-A279-0ED807665387Q33396369-C65E89C0-D2EB-46D3-9A24-DAF8F7C7BC8FQ33408049-9BC105E7-D1C0-46AE-800B-426202DA7641Q33408836-4FEED4EB-463D-4798-B784-C32F11CDA5A5Q33564645-EFD0BA29-D430-4571-BB99-78A61BC34966Q33631305-C79DA883-C45B-4943-A622-236D2765A548Q33699582-2B9B1499-98C9-4DE0-A0F3-5968EA1E75FAQ33930609-CEEA3BA7-E24C-4BE6-A75A-853D5D7CC78BQ33949406-E37FA953-AD93-40F7-B4CC-BC8593A4E286Q34105997-1BD0F25E-CD25-4230-BD07-4849CABA6FFDQ34115840-E3B11B61-3F2A-43BF-BA34-15E7B4951F51Q34208140-1946DC7D-3F02-41BF-B644-C954836F025CQ34286194-AE082E9E-5076-4BF3-9FA5-80716A78B554Q34554380-2F848137-D271-4B44-B248-B081355808E6Q34593475-DCE37CDB-E2A2-4D41-9932-868C584333E0
P2860
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@ast
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@en
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@nl
type
label
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@ast
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@en
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@nl
prefLabel
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@ast
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@en
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@nl
P2093
P921
P356
P1476
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
@en
P2093
Sanjaykumar Hapani
Shenhong Wu
Vishal Ranpura
P304
P356
10.1001/JAMA.2011.51
P407
P577
2011-02-01T00:00:00Z